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Central insulin action activates hepatic IL-6/STAT3
signaling, which suppresses the gene expression of
hepatic gluconeogenic enzymes. The vagus nerve
plays an important role in this centrally mediated he-
patic response; however, the precisemechanism un-
derlying this brain-liver interaction is unclear. Here,
we present our findings that the vagus nerve sup-
presses hepatic IL-6/STAT3 signaling via a7-nico-
tinic acetylcholine receptors (a7-nAchR) on Kupffer
cells, and that central insulin action activates
hepatic IL-6/STAT3 signaling by suppressing vagal
activity. Indeed, central insulin-mediated hepatic
IL-6/STAT3 activation and gluconeogenic gene sup-
pression were impeded in mice with hepatic vagot-
omy, pharmacological cholinergic blockade, or
a7-nAchR deficiency. In high-fat diet-induced obese
and insulin-resistant mice, control of the vagus
nerve by central insulin action was disturbed,
inducing a persistent increase of inflammatory cyto-
kines. These findings suggest that dysregulation of
the a7-nAchR-mediated control of Kupffer cells by2362 Cell Reports 14, 2362–2374, March 15, 2016 ª2016 The Authorcentral insulin action may affect the pathogenesis
of chronic hepatic inflammation in obesity.INTRODUCTION
Insulin directly controls glucose metabolism in various target or-
gans such as skeletal muscle, adipose tissue, and the liver, while
also acting indirectly on the CNS to regulate glucose/energy
metabolism (Plum et al., 2006; Schwartz et al., 2013). In fact,
brain-specific insulin receptor knockout mice display insulin
resistance, in addition to increased food intake, body weight,
and obesity (Br€uning et al., 2000). Various studies have indicated
that central insulin action reduces hepatic glucose production
(HGP), especially in rodents (Obici et al., 2002). Increased circu-
lating levels of insulin result in the activation of hypothalamic in-
sulin receptor/phosphatidylinositol 3-kinase (PI3-K) signaling,
leading to the suppression of HGP via hypothalamic ATP-depen-
dent potassium channels, which is activated by PI3-K (Carey
et al., 2013; Prodi and Obici, 2006). Indeed, the suppression of
HGP using the hyperinsulinemic-euglycemic clamp technique
is impeded by insulin receptor deficiency, insulin receptor
knockdown, and PI3-K inhibition in the hypothalamus (Inoue
et al., 2006; Obici et al., 2002). Moreover, intracerebroventricular
(ICV) administration of insulin and ATP-dependent potassiums
Figure 1. Central Insulin Action Suppresses Hepatic Vagal Activation, which Inhibits Hepatic IL-6/STAT3 Signaling
(A) Hepatic VNA after ICV insulin or artificial cerebrospinal fluid (aCSF) administration. The time-course changes in hepatic VNA after injection of aCSF or insulin
are expressed as mean ± SE of the percentages of values at 0 min are shown on the left. The open circles are 2 ml of aCSF ICV bolus injection (n = 6). The closed
circles are 40 mU/2 ml of insulin ICV bolus injection (n = 6) (significant differences between the aCSF group and insulin group from 30–180 min) (p < 0.05).
A representative neurogram depicting the effect of ICV aCSF and insulin in mice is shown on the right.
(legend continued on next page)
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channel activators reportedly reduce HGP (Obici et al., 2002; Po-
cai et al., 2005a). Several studies have revealed that ICV insulin-
induced suppression of HGP is abolished by hepatic vagotomy,
suggesting that central insulin action-induced hepatic responses
are mediated by the vagus nerve (Pocai et al., 2005a, 2005b).
Central insulin action suppresses HGP by downregulating the
gene expression of gluconeogenic enzymes such as G6pc,
which encodes glucose-6-phosphatase (G6Pase). Previously,
we reported the importance of hepatic IL-6/STAT3 signaling as
an effector of the central insulin action-mediated hepatic
response (Inoue et al., 2006). STAT3 is a ligand-dependent tran-
scription factor that is phosphorylated via ligands such as inter-
leukin-6 (IL-6) to become activated as a transcription factor
(Akira, 1997). The expression of IL-6 in hepatic resident macro-
phages, Kupffer cells, increases following central insulin action,
which leads to the paracrine activation of hepatocyte STAT3 and
the subsequent suppression of gluconeogenic enzyme gene
transcription (Inoue et al., 2004, 2006). It has also been reported
that activated STAT3 binds to the promoter region of the G6pc
gene to suppress its transcription (Ramadoss et al., 2009).
Furthermore, hepatic STAT3 deficiency or systemic IL-6 defi-
ciency results in insulin resistance and impaired suppression of
HGP by ICV insulin, suggesting the importance of central insulin
action-mediated hepatic IL-6/STAT3 signaling (Inoue et al.,
2006). While the mechanism of insulin action in the CNS and
the importance of hepatic IL-6/STAT3 signaling in the suppres-
sion of central insulin action-mediated HGP are being clarified,
the mechanism of central insulin action-mediated control on
the vagus nerve and hepatic IL-6/STAT3 signaling has not
been elucidated fully.
The vagus nerve is known to perform crucial functions in
modulating inflammation (Borovikova et al., 2000). In particular,
electrical stimulation of the vagus nerve reportedly suppresses
the induction of inflammatory cytokine expression including
IL-6 in the liver following lipopolysaccharide (LPS) administration
(Borovikova et al., 2000). Acetylcholine, which is the main
neurotransmitter in the vagus nerve, reportedly suppresses the
secretion of IL-6 via the a7-nicotinic acetylcholine receptor
(a7-nAchR) in peritoneal macrophages (Wang et al., 2003).
Indeed, the administration of LPS results in a higher blood con-
centration of IL-6 in a7-nAchR knockout (a7KO) mice than in
controls (Wang et al., 2003). It has also been pointed out that
the inflammation control mechanism of the vagus nerve serves
an important role as a feedback mechanism in the inflammatory(B and C) Wild-type (WT) mice were vagotomized or sham-operated and then
levels were determined at 4 days after vagotomy by western blotting (B), and t
(*p < 0.05) (n = 8).
(D and E) Time-course changes in STAT3 phosphorylation and hepatic Il6 mRN
phosphorylation levels were determined by western blotting (D, lysates were poole
qRT-PCR (*p < 0.05) (n = 6–10).
(F) Time-course change in STAT3 phosphorylation after chlorisondamine admini
toneally. The liver was harvested at the indicated time, and the STAT3 phosphoryl
group). The quantitation of STAT3 phosphorylation levels is normalized to total S
(G and H) The mice were pre-treated with liposome-encapsulated clodronate a
harvested at 4 hr after administration, and the STAT3 phosphorylation levels w
expression levels of IL-6 and Emr1 (H) were measured by qRT-PCR (*p < 0.05) (n =
VNA, HVNA; insulin, Ins; vehicle, Veh; and vagotomy, Vx).
See also Figure S1.
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kines (Tracey, 2002). However, the role of the vagal control of
Kupffer cells in physiological inter-organ communication be-
tween the CNS and liver has yet to be elucidated.
In this study, we found that the vagal Kupffer cell-suppressing
action plays an important role in the central insulin action-medi-
ated hepatic responses of IL-6/STAT3 signal activation and
regulation of gluconeogenic enzyme gene expression. Central
insulin action activates hepatic IL-6/STAT3 signaling by sup-
pressing the activity of the hepatic branches of the vagus nerve
and alleviating the vagal suppression of Kupffer cells. Moreover,
we found that a7-nAchR is essential for central insulin action-
mediated hepatic responses, as these responses were severely
impeded in a7KO mice.
RESULTS
Central Insulin Action Suppresses Hepatic Vagal
Activation, Inhibiting Hepatic IL-6/STAT3 Signaling
To investigate the regulation of vagus nerve activation by central
insulin action, electrophysiological activity of the hepatic
branches of the vagus nerve was measured under ICV insulin.
Vagal nerve activity (VNA) of the hepatic branches diminished
significantly in the ICV insulin group from 30min after administra-
tion (Figure 1A). Therefore, we performed a hepatic branch
vagotomy study to investigate the effect of diminished VNA on
hepatic IL-6/STAT3. Vagotomy enhanced STAT3 phosphoryla-
tion and IL-6 expression in the liver (Figures 1B, S1A, and
S1C). It is known that intravenous administration of liposome-
encapsulated clodronate enables the removal of Kupffer cells,
which are the major source of IL-6 in the liver (Kimura et al.,
2013; Van Rooijen and Sanders, 1996), and indeed, in the
present study, liposome-encapsulated clodronate treatment
reduced the expression of the Kupffer cell and macrophage
markers Emr1 and IL-6 in the liver, but not in adipose tissue
or the spleen (Figures 1C and S1B). Immunohistochemical anal-
ysis using an anti-MAC2 antibody, which is used widely for the
detection of monocytes/macrophages/Kupffer cells, also re-
vealed the marked decrease of MAC2-positive cells in the liver
following liposome-encapsulated clodronate treatment (Fig-
ure S1C). Following the reduction of hepatic IL-6 expression by
the administration of liposome-encapsulated clodronate, vagot-
omy-induced hepatic STAT3 phosphorylation was diminished
(Figures 1B, S1A, and S1C). Hepatic branch vagotomy resultedtreated with liposome-encapsulated clodronate. The STAT3 phosphorylation
he gene expression levels of Emr1 and IL-6 (C) were measured by qRT-PCR
A after vagotomy. The liver was harvested at the indicated time, the STAT3
d for each group), and the gene expression levels of IL-6 (E) were measured by
stration. The mice were administered chlorisondamine (0.25 mg/kg) intraperi-
ation levels were determined by western blotting (lysates were pooled for each
TAT3 (right) (*p < 0.05) (n = 6).
nd then given chlorisondamine (0.25 mg/kg) intraperitoneally. The liver was
ere determined by western blotting and quantitative densitometry. (G) Gene
6) (chlorisondamine, chlori; liposome-encapsulated clodronate, CLD; hepatic
s
(legend on next page)
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in enhanced hepatic STAT3 phosphorylation from 12 hr after
excision, as well as a significant increase in hepatic IL-6 gene
expression from 24 hr after excision (Figures 1D, S1D, and
S1E). The surgical procedure, which induced acute and transient
hepatic STAT3 phosphorylation in a vagotomy-independent
manner, as shown by its phosphorylation until 12 hr after laparot-
omy in sham surgery groups (Figures 1D and S1D), prevented us
from assessing the acute effects of vagal inactivation on hepatic
IL-6/STAT3 activation. Therefore, we performed an investigation
using chlorisondamine, which is a a7-nAchR antagonist, to
evaluate the effect of acute blockage of vagal nicotinic cholin-
ergic action on hepatic IL-6/STAT3. At low doses, chlorisond-
amine mainly blocks the effects of peripheral a7-nAchR, similar
to an autonomic ganglion blocker (Clarke, 1984; Clarke et al.,
1994). Hepatic STAT3 was phosphorylated from 3 to 12 hr
after peripheral nicotinic cholinergic blockade by low-dose
chlorisondamine administration (Figure 1F), and the increase
of hepatic STAT3 phosphorylation by chlorisondamine admin-
istration was attenuated following the administration of lipo-
some-encapsulated clodronate (Figure 1G). Chlorisondamine
administration also increased IL-6 gene expression in the liver;
however, liposome-encapsulated clodronate administration
greatly diminished hepatic IL-6 expression, along with that of
Emr1 (Figure 1H). These results suggest that central insulin ac-
tion suppresses vagus nerve activity and that the decline in its
activity induces the increase of IL-6 expression in Kupffer cells
and hepatic STAT3 phosphorylation.
Vagal Blockade Abolishes Central Insulin-Mediated
Regulation of Hepatic IL-6/ STAT3 Signaling and
Gluconeogenic Gene Expression
ICV insulin induced STAT3 phosphorylation and IL-6 gene
expression in the liver and suppressed the gene expression of
G6Pase, a hepatic gluconeogenic enzyme (Figures 2A and
S2A–S2C). Therefore, the role of the vagus nerve in central insu-
lin action-mediated hepatic responses was investigated by
vagotomy and chlorisondamine administration. At 4 days after
vagotomy, STAT3 phosphorylation and IL-6 expression were
slightly increased in the liver, but the hepatic IL-6/STAT3 signal
activation response to ICV insulin administration was lost (Fig-
ures 2A, S2A, and S2B). In keeping with previous reports (Pocai
et al., 2005b), vagotomy inhibited the ICV insulin-induced sup-
pression of G6Pase gene expression (Figure 2C). Chlorisond-
amine administration increased hepatic STAT3 phosphorylationFigure 2. Vagal Blockade Abolishes Central-Insulin Mediated Regu
Expression
(A–C) ICV insulin administration was performed at 4–6 days after vagotomy. The W
administration, and the STAT3 phosphorylation levels were determined by wes
measured by qRT-PCR (*p < 0.05) (n = 11).
(D–F) Chlorisondamine (0.25mg/kg) was injected intraperitoneally at 1 hr before in
and the STAT3 phosphorylation levels were determined by western blotting (D). T
PCR (*p < 0.05) (n = 12).
(G–O) Neostigmine (G and H; 0.02 mg/kg), nicotine (I and J; 0.2 mg/kg), betha
intraperitoneally at 15 min before insulin (10 mU/hr, ICV). The liver was harves
determined by western blotting and quantitative densitometry (G, I, K, and M). The
qRT-PCR (*p < 0.05) (G and H, n = 9; I and J, n = 15; K and L, n = 10; and M–O,
neostigmine, Neos; nicotine, Nic; sham vagotomy, Sham; and vagotomy, Vx).
See also Figure S2.
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ure 2E), and decreased G6Pase gene expression (Figure 2F).
Yet, no additive effects were observed on hepatic responses
by central insulin action under chlorisondamine administration,
such as increased hepatic STAT3 phosphorylation and IL-6
gene expression or suppressed G6Pase expression (Figures
2D, S2B, S2E, and S2F). These results suggest that the vagus
nerve suppresses IL-6/STAT3 signaling in the liver, and by inhib-
iting this suppression by the vagus nerve, central insulin action
induces hepatic effects such as IL-6/STAT3 signal activation
and the suppression of G6Pase gene expression.
The role of acetylcholine, which is the major neurotransmitter
in the vagus nerve, in ICV insulin-induced hepatic IL-6/STAT3
activation was investigated. Amplification of its cholinergic effect
via administration of the acetylcholinesterase inhibitor neostig-
mine diminished the ICV insulin-induced phosphorylation of he-
patic STAT3 (Figure 2G). The ICV insulin-induced increase of IL-6
gene expression did not occur under neostigmine administration
(Figure 2H). Moreover, central insulin action-mediated activation
of hepatic IL-6/STAT3 signaling was inhibited by the administra-
tion of nicotine (Figures 2I and 2J). These results indicate
that central insulin action may control IL-6 gene expression in
Kupffer cells and STAT3 activation in hepatocytes via nicotinic
cholinergic action. While the enhanced cholinergic action
following neostigmine reduced hepatic STAT3 phosphorylation,
administration of the muscarinic acetylcholine receptor agonist
bethanechol increased hepatic IL-6 expression and STAT3
phosphorylation (Figures 2K and 2L). The muscarinic acetylcho-
line receptor antagonist, atropine, inhibited bethanecol-induced
hepatic STAT3 activation (Figure S2C), but had no effect on ICV
insulin-induced hepatic STAT3 phosphorylation, IL-6 increase,
or G6pc decrease (Figures 2M–2O).
a7 Nicotinic Cholinergic Action Suppresses Kupffer Cell
Activation
We investigated the suppressing effect of nicotinic cholinergic ac-
tivity on IL-6 expression in isolated Kupffer cells. Acetylcholine
reduced the LPS-dependent induction of IL-6 expression in iso-
lated Kupffer cells (Figure 3A). Moreover, the LPS-dependent
inductionof IL-6 expressionwas suppressed in adose-dependent
mannerwith nicotine pre-treatment, but notwith bethanechol pre-
treatment (Figure 3B). Nicotine suppressed IL-6 expression, but
this suppression was mitigated by chlorisondamine (Figure 3C).
Next, we performed an investigation using a-bungarotoxinlation of Hepatic IL-6/STAT3 Signaling and Gluconeogenic Gene
T mice were given ICV insulin (10 mU/hr). The liver was harvested at 3 hr after
tern blotting (A). The gene expression levels of IL-6 (B) and G6Pase (C) were
sulin (10 mU/hr, ICV). The liver was harvested at 3 hr after insulin administration,
he expression levels of IL-6 (E) and G6Pase (F) mRNA were measured by qRT-
nechol (K and L; 3 mg/kg), and atropine (M and N; 0.1 mg/kg) were injected
ted at 3 hr after administration, and the STAT3 phosphorylation levels were
gene expression levels of IL-6 (H, J, L, and N) and G6pc (O) were measured by
n = 6) (atropine, Atro; bethanechol, Beth; chlorisondamine, Chlori; insulin, Ins;
s
Figure 3. a7 Nicotinic Cholinergic Action
Suppresses Kupffer Cell Activation
(A and B) Isolated Kupffer cell Il6 mRNA levels
stimulated by LPS after 15 min pre-treatment with
acetylcholine (1, 10, and 100 mM with 1 mM pyri-
dostigmine) (A), or with bethanechol (1, 10, and
100 mM), or nicotine (0.01, 0.1, and 1 mM) (B)
(*p < 0.05) (n = 4–6).
(C and D) Gene expression levels of IL-6 in isolated
Kupffer cells after LPS stimulation with 15 min pre-
treatment of chlorisondamine (10, 30, and 100 mM)
and/or nicotine (0.1 mM) (C) and with 15 min pre-
treatment with MLA (1 mM) or DHbE (1 mM, 15 min)
or aBgt (100 nM) and/or nicotine (0.1 mM) (D)
(*p < 0.05) (n = 6).
(E) Isolated Kupffer cells were stimulated with LPS
following 15 min pre-treatment with PNU-282987
(PNU; 0.1, 1, and 10 mM). The gene expression of
IL-6 in Kupffer cells was measured by qRT-PCR
(*p < 0.05) (n = 6).
(F) In WT or a7KO mouse-derived Kupffer cells, Il6
mRNA levels were measured after LPS stimulation
with 15 min of nicotine pre-treatment (0.1 mM;
*p < 0.05; n = 13). a-Bgt; acetylcholine, Ach; be-
thanechol, Beth; chlorisondamine, Chlori; DhbE;
and nicotine, Nic.(aBgt), an inhibitor of the a1, a7, and a8 a7-nAchR subtypes;
methyllycaconitine (MLA), an antagonist of the a7 receptor sub-
type (a7-nAchR); dihydro-b-erythroidine (DHbE), an antagonist of
the a4b2 receptor, the predominant nAchR in the CNS (Holladay
et al., 1997); and PNU-282987, an agonist of a7-nAchR (Bodnar
et al., 2005;Holladayet al., 1997). Thenicotine treatment-induced
suppression of IL-6 expression was mitigated by aBgt and
MLA, but DHbE had no effect (Figure 3D). The LPS-dependent
induction of IL-6 expression was suppressed in a dose-depen-
dentmanner byPNU-282987 (Figure 3E).Moreover, the suppres-
sive effect of nicotine on the LPS-dependent induction of IL-6
expression was lost in Kupffer cells isolated from a7KO mice
(Figures 3F and S3A). These results suggest that acetylcholine
suppressed IL-6 expression in Kupffer cells via a7-nAchR.
Ablation of a7 Cholinergic Action Impedes Hepatic
Regulation of IL-6/STAT3 Activation and Gluconeogenic
Gene Expression Induced by Central Insulin Action
The importance of a7-nAchR in the central insulin action-medi-
ated hepatic response was investigated using PNU-282987
and MLA. Central insulin action-mediated hepatic IL-6/STAT3
activation was lost when PNU-282987 was administered (Fig-
ures 4A and 4B). Meanwhile, MLA administration enhancedCell Reports 14, 2362–2374IL-6 expression and STAT3 activation in
the liver, but did not further increase the
central insulin action-mediated upregula-
tion of hepatic IL-6/STAT3 signal activa-
tion (Figures 4C and 4D). a7KO mice
reportedly display glucose intolerance
and insulin resistance following high-fat
diet feeding (Wang et al., 2011). However,
when kept on a standard diet, there wasno significant difference between a7KO mice and controls in
terms of body weight and blood glucose levels under ad libitum
feeding or in their blood glucose and plasma insulin levels during
a glucose tolerance test (Figures S3A–S3F). Genetic ablation of
a7-nAchR increased hepatic STAT3 phosphorylation similarly
to acute inhibition by MLA administration, though STAT3 phos-
phorylation in a7KO mice was milder than that following MLA
administration (Figure 4E). Additionally, when ICV insulin was
administered, a7KO mice displayed suppression of vagus nerve
activity similar to wild-type mice, but the increase of hepatic IL-6
expression and STAT3 activation was diminished (Figures 4E–
4G). Furthermore, the suppression of G6Pase expression
caused by ICV insulin was impeded in a7KO mice compared
with controls (Figure 4H). These results suggest that a7-nAchR
contributes significantly to the central insulin action-mediated
activation of hepatic IL-6/STAT3 signaling and suppression of
G6Pase gene expression.
Reconstitution of Kupffer Cells with Wild-type Bone
Marrow-Derived Cells Restores the Central Insulin-
Induced Activation of Hepatic Responses in a7KO Mice
a7-nAchR is expressed in the CNS, autonomic ganglia, andmac-
rophages (Holladay et al., 1997;Wang et al., 2003). To investigate, March 15, 2016 ª2016 The Authors 2367
Figure 4. Ablation of a7 Cholinergic Action
Attenuates IL-6/STAT3 Activation and Glu-
coneogenic Suppression Induced by Cen-
tral Insulin Action
(A and B) STAT3 phosphorylation (A) and Il6mRNA
(B) in the liver were measured at 3 hr after ICV in-
sulin administration with 15 min subcutaneous
pre-treatment of PNU (20 mg/kg; *p < 0.05; n = 9).
(C and D) STAT3 phosphorylation (C) and Il6mRNA
(D) in the liver were measured at 3 hr after ICV in-
sulin administration with 15 min intraperitoneal
pre-treatment of MLA (0.1 mg/kg; *p < 0.05; n = 8).
(E, G, and H) STAT3 phosphorylation (E), Il6mRNA
(G), and G6pc (H) mRNA in the liver of WT mice or
a7KO mice were measured at 3 hr after ICV insulin
administration. (E) Quantitation of STAT3 phos-
phorylation levels is normalized to total STAT3
(right; *p < 0.05; n = 13).
(F) Effects of insulin injection on hepatic VNA in
mice. The time-course changes in hepatic VNA
after ICV insulin injection to WT or a7KO mice are
expressed as mean ± SEM of the percentages of
values at 0 min. The open circles are ICV insulin
injection to WT mice (n = 5), and the closed circles
are ICV insulin injection to a7KO mice (n = 5).
Hepatic VNA, HVNA and insulin, Ins.
See also Figure S3.the importance of Kupffer cell a7-nAchR in central insulin action-
mediated hepatic responses, we performed Kupffer cell replace-
ment by bone marrow transplantation, and then tested the
hepatic response to ICV insulin. Bone marrow transplantation
with liposome-encapsulated clodronate treatment enables the
reconstitution of Kupffer cells in recipient mice, in addition to he-
matopoietic cells, with those of donor mice (Seki et al., 2009).
After bone marrow transplantation from eGFP transgenic mice
to a7KO mice, 91.4% ± 3.3% (n = 3) of Kupffer cells in recipient
a7KO mice were replaced with eGFP-positive Kupffer cells (Fig-
ure 5A) and a7-nAchR expression recovered in Kupffer cells iso-
lated from recipient a7KO mice (Figure 5B). Replacement of
a7KO Kupffer cells with their wild-type counterparts by trans-
planting wild-type mouse-derived bone marrow resulted in the
recovery of the ICV insulin-induced hepatic responses of hepatic
IL-6/STAT3 activation and G6Pase decrease (Figures 5C–5E).
To assess the role of Kupffer cell a7-nAchR in central insulin-
mediated HGP regulation, we measured endogenous glucose2368 Cell Reports 14, 2362–2374, March 15, 2016 ª2016 The Authorsproduction (EGP) in mice that underwent
bone marrow transplantation, by a
combination of ICV insulin infusion with
pancreatic-insulin clamp studies (Fig-
ure 6A), as described previously (Inoue
et al., 2006; Obici et al., 2002). In the pro-
tocol, plasma insulin levels were set to
0.466 ± 0.091 ng/ml (n = 6) in wild-type
mice at 120 min after the start of intrave-
nous insulin infusion. There was no signif-
icant difference in blood glucose levels
between wild-type mice with wild-type
bone marrow, a7KO mice with a7KObone marrow, and a7KO mice with wild-type bone marrow at
the basal state 240 min after the start of ICV insulin infusion
and the clamp state between 90 and 120 min after starting intra-
venous insulin (Figures 6B and 6C). a7KO mice with a7KO bone
marrow had a lower glucose infusion rate with impeded ICV insu-
lin-induced suppression of EGP than wild-type mice with wild-
type bone marrow transplantation, with no significant difference
in the rate of disappearance (Figures 6D–6F). Reconstitution of
wild-type Kupffer cells in a7KOmice by bone marrow transplan-
tation restored the central insulin-mediated suppression of EGP
(Figure 6F). These findings indicate that Kupffer cell a7-nAchR
plays a significant role in the central insulin-mediated regulation
of HGP.
Central Insulin-Mediated Vagal Suppression Is Blocked
in Obese Insulin-Resistant Mice
Central insulin action-mediated metabolic control is impeded in
obesity and insulin resistance (Ono et al., 2008; Spanswick et al.,
Figure 5. Reconstitution of WT Kupffer Cells in a7KO Mice Restores Central Insulin-Induced Hepatic IL-6/STAT3 Activation
(A) Hepatic Kupffer cells were analyzed by immunostaining using anti-MAC2 and anti-GFP antibodies in a7KO mice transplanted with GFP-transgenic mice-
derived bone marrow. The scale bar represents 100 mm.
(B) Gene expression of a7-nAchR in brain and Kupffer cells and of Emr1 in the liver ofWTmice withWTbonemarrow transplantation (BMT) (n = 6), a7KOmice with
a7KO-BMT (n = 7), or WT-BMT mice (n = 6).
(C–E) STAT3 phosphorylation (C), Il6 mRNA (D), and G6pc mRNA (E) levels in mice with Kupffer cell reconstitution after ICV insulin administration (*p < 0.05;
n = 6–10).
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Figure 6. Reconstitution of WT Kupffer
Cells Restores Central Insulin-Mediated
Suppression of EGP in a7KO Mice
(A) A euglycemic pancreatic-insulin clampwith ICV
insulin infusion was performed as shown in the
schematic.
(B–F) Blood glucose levels before (B) and during
the last 30 min of the euglycemic clamp tests (C),
glucose infusion rate (GIR) (D), rate of disappear-
ance (Rd) (E), and EGP before and after intrave-
nous insulin infusion (F) (*p < 0.05; n = 6).2000). Indeed, ICV insulin does not lead to a change in vagus
nerve activity, and the suppression of G6Pase gene expression
is impeded (Figures 7A and 7B) in mice displaying obesity and
hyperinsulinemia after receiving a high-fat diet for 6 weeks (Fig-
ures S4A–S4C). Hepatic expression of IL-6 was amplified inmice
with high-fat diet feeding, but the increased expression of IL-6
normally induced by ICV insulin was lost (Figure 7B). Chlorisond-
amine administration resulted in increased hepatic expression of
IL-6 in lean mice due to the acute alleviation of the vagal sup-
pression of Kupffer cells, but resulted in no change in high-fat
diet-induced obese mice (Figure 7C). Meanwhile, PNU adminis-
tration lowered the increased expression of IL-6 in the liver of
high-fat diet mice (Figure 7D), suggesting that a cholinergic
effect leads to Kupffer cell suppression even in diet-induced
obese mice. Together, these results suggest that central insulin
action-mediated vagus nerve control is lost, and that the sup-
pression of IL-6 expression in Kupffer cells by the vagus nerve
is impeded in obese insulin-resistant mice.
DISCUSSION
Autonomic nerve-mediated crosstalk between the CNS and
peripheral organs serves an important function in the mainte-
nance of glucose/energy metabolism homeostasis by insulin.
In particular, the importance of the vagus nerve in the central in-
sulin action-mediated suppression of HGP has been indicated2370 Cell Reports 14, 2362–2374, March 15, 2016 ª2016 The Authorsby previous studies of hepatic vagotomy
(Pocai et al., 2005b). In a previous report,
we showed that central insulin action
suppresses the gene transcription of
hepatic gluconeogenic enzymes via the
activation of hepatic IL-6/STAT3 sig-
naling, that is, increased IL-6 expression
in Kupffer cells and activation of hepato-
cyte STAT3 (Inoue et al., 2006). The in-
duction of hepatic IL-6/STAT3 signaling
activation by central insulin action has
been confirmed in dogs as well as in ro-
dents, suggesting the interspecies con-
servation of the mechanism of the central
insulin action-mediated hepatic response
(Ramnanan et al., 2011). However, the
molecular mechanism by which central
insulin action elicits hepatic responses
via the vagus nerve has not yet beenelucidated. In this study, we showed that central insulin sup-
presses vagus nerve activity, resulting in hepatic IL-6/STAT3
activation and HGP decrease via a7-nAchR. A recent paper
suggested that the activity of the vagus nerve is suppressed
by activation of the melanocortin 4 receptor, a receptor of a-me-
lanocyte-stimulating hormone (a-MSH) (Sohn et al., 2013), and it
has been also reported that central administration of a-MSH de-
creases HGP (Obici et al., 2001). These findings may be related
to our present finding that the suppression of vagus nerve activ-
ity results in decreased HGP, though it has been indicated that
central insulin action suppresses HGP in an a-MSH-indepen-
dent manner (Obici et al., 2002).
Insulin action in hypothalamic agouti-related peptide (AgRP)
neurons reportedly has a significant role in central insulin-medi-
ated HGP suppression. In AgRP neuron-specific insulin receptor
KO mice, the insulin-dependent suppression of HGP is impeded
during euglycemic hyperinsulinemic clamp studies (Ko¨nner
et al., 2007). The insulin-mediated decrease of HGP is not
impeded in proopiomelanocortin (POMC) neuron-specific insulin
receptor KO mice (Ko¨nner et al., 2007), but is impaired in POMC
neuron-specific leptin receptor/insulin receptor double KO mice
(Hill et al., 2010), possibly indicating the importance of hypotha-
lamic POMC neurons. We revealed that ICV insulin suppressed
the activity of the hepatic branches of the vagal nerve, but eluci-
dation of a vagus nerve regulation mechanism by insulin in the
CNS remains a future challenge.
Figure 7. Central Insulin-Mediated Vagal Suppression Is Blocked in
Obese Insulin-Resistant Mice
(A) Hepatic VNA in diet-induced obesity (DIO) insulin-resistant mice after ICV
insulin infusion. The data are expressed as mean ± SE of the percentages of
values at 0 min. The open circles are ICV-aCSF bolus injection to lean mice
(n = 6). The closed circles are ICV insulin injection to lean mice (n = 6). The gray
squares are ICV insulin injection to DIO mice (n = 6).
(B) Gene expression levels of IL-6 and G6Pase in lean and DIO mice with ICV
insulin (*p < 0.05; n = 14).
(C and D) Gene expression levels of IL-6 in lean and DIO mice at 4 hr after
intraperitoneal administration of chlorisondamine (0.25 mg/kg; C; n = 9) or at
3 hr after subcutaneous administration of PNU (20 mg/kg; D; n = 11–13;
*p < 0.05). Insulin, Ins; hepatic VNA, HVNA; and vehicle, Veh.
See also Figure S4.The acute shutdown of vagal cholinergic activity by the admin-
istration of the a7-nAchR antagonist chlorisondamine resulted in
increased hepatic IL-6 expression and STAT3 phosphorylation.
Meanwhile, the administration of liposome-encapsulated clodr-
onate, which depletes Kupffer cells in the liver, but not macro-
phages in adipose tissue, abrogated both the hepatic increase
of IL-6 expression and STAT3 phosphorylation induced by chlor-
isondamine administration. These findings indicate that sup-Cellpression of vagal action can increase IL-6 expression in Kupffer
cells, which induces hepatic STAT3 phosphorylation. As a previ-
ous study reported that STAT3 phosphorylation appears for a
brief period and declines thereafter by persistent stimulation of
IL-6 (Lang et al., 2003), the cellular responses to IL-6 are different
between chronic persistent and acute stimulation of IL-6 (Awa-
zawa et al., 2011). Indeed, chronic inhibition of vagus nerve
activity by vagotomy leads to a persistent increase of IL-6
expression, but a much milder enhancement of hepatic STAT3
phosphorylation, at more than 24 hr after vagotomy, which
would not be sufficient to decrease G6Pase expression. The in-
crease of IL-6 expression in Kupffer cells by suppression of
vagus nerve activity may decay with time, whereas the ablation
of the vagal control of Kupffer cells persists. Indeed, hepatic
IL-6/STAT3 signaling was activated as potently by the acute
inhibition of a7-nAchR by MLA as by chlorisondamine adminis-
tration, while the chronic disruption of a7-nAchR in a7KO mice
revealed no significant increase in hepatic IL-6 expression and
much milder activation of hepatic STAT3 as compared with
chronic vagal inhibition by vagotomy. In fact, a7-nAchR defi-
ciency resulted in no difference of G6Pase expression in the fast-
ing state compared with controls. ICV insulin attenuated vagus
nerve activity, followed by hepatic IL-6/STAT3 activation. How-
ever, with vagal blockage, namely via chlorisondamine adminis-
tration or vagotomy, the ICV insulin-mediated boost of hepatic
IL-6/STAT3 signaling activation was inhibited. These results sug-
gest that the suppressive action of the vagus nerve on IL-6
expression in Kupffer cells plays an important role in central insu-
lin action-mediated hepatic responses. Meanwhile, vagotomy
failed to increase hepatic IL-6/STAT3 activation under the condi-
tion of ICV insulin, which may suggest the existence of a central
insulin action-mediated counter regulatory mechanism that sup-
presses hepatic IL-6/STAT3 signaling.
The central insulin action-mediated hepatic response of IL-6/
STAT3 activation amplification was lost with the administration
of chlorisondamine or MLA and suppressed with the administra-
tion of nicotine and PNU-282987. In a7KO mice, the ICV insulin-
induced hepatic activation of STAT3 and suppressed expression
of G6Pase were impeded. These findings suggest that vagal
a7-nAchR action plays an important role in central insulin
action-mediated hepatic responses. The vagus nerve forms syn-
apses with post-synaptic fibers at the intrahepatic autonomic
ganglia. a7-nAchR is also expressed in the ganglia, as in Kupffer
cells (McCuskey, 2004; Uyama et al., 2004). In primary cultures
of Kupffer cells, LPS-dependent inflammatory cytokine ex-
pression was suppressed by the action of a7-nAchR. Addition-
ally, replacement of Kupffer cells in a7KO mice with wild-type
counterparts led to the recovery of ICV insulin-induced IL-6/
STAT3 activation and HGP suppression. These observations
are indicative of the importance of Kupffer cell a7-nAchR in
central insulin action-mediated hepatic responses. In contrast,
the role of muscarinic cholinergic action in centrally mediated
hepatic responses remains to be elucidated. The muscarinic
acetylcholine receptor antagonist, atropine, had no effect on
the ICV insulin-induced increase of IL-6 expression and STAT3
phosphorylation in the liver at the dose at which bethanecol-
induced hepatic STAT3 phosphorylation was inhibited. How-
ever, the enhanced cholinergic action following neostigmineReports 14, 2362–2374, March 15, 2016 ª2016 The Authors 2371
administration potently decreased hepatic IL-6/STAT3 activa-
tion; conversely, the enhanced muscarinic cholinergic action
following bethanechol administration increased hepatic IL-6/
STAT3 activation, though bethanechol treatment had little influ-
ence on the LPS-induced expression of IL-6 in isolated Kupffer
cells. These findings may indicate that muscarinic cholinergic
action acts as a feedforward mechanism of nicotinic cholinergic
action in centrally medicated hepatic responses.
Obesity and insulin resistance impair central insulin action in
the hypothalamus (Ono et al., 2008; Spanswick et al., 2000).
Indeed, our investigation showed that ICV insulin failed to
elicit changes in vagus nerve activity of high-fat diet-induced
obese mice. Hepatic IL-6 expression was suppressed by PNU-
282987 administration in high-fat diet-induced obese mice, sug-
gesting that cholinergic action suppresses IL-6 expression even
in obese and insulin-resistant mice. However, hepatic IL-6
expression was not amplified by acute blockade of vagal
cholinergic action by chlorisondamine administration in high-
fat diet-induced obese mice, indicating that the vagal control
of suppressing IL-6 expression in hepatic Kupffer cells was
disrupted in obese mice in the samemanner as in hepatic vagot-
omy. In obesity-induced insulin resistance, metabolites and
humoral factors, including free fatty acids and tumor necrosis
factor, lead to chronic inflammation in the liver, which exacer-
bates hepatic insulin resistance (Gregor and Hotamisligil,
2011). Although a7-nAchR deficiency did not enhance hepatic
IL-6 expression, possibly due to prolonged ablation of the vagal
control of Kupffer cells, the inflammation-induced increases of
hepatic inflammatory cytokines are reportedly upregulated in
a7KOmice (Wang et al., 2003). In addition to these proinflamma-
tory stimuli, such as metabolites and humoral factors resulting
from obesity and insulin resistance, it is plausible that the impair-
ment of central insulin-mediated vagal action via a7-nAchR that
suppresses hepatic inflammatory cytokine expression contrib-
utes to chronic hepatic inflammation. In obesity and insulin-
resistance, hepatic IL-6 increase failed to reduce G6Pase gene
expression. As shown in our vagotomy experiments, the persis-
tent increase of IL-6 expression revealed much milder activation
of hepatic STAT3 than the acute increase of IL-6 induced by
acute blockade of cholinergic action. Furthermore, it has been
reported that a low-grade proinflammatory state in obese mice
results in a mild increase in the basal activation and blunting of
the acute activation response of hepatic STAT3 by IL-6 (Gruber
et al., 2013; Kimura et al., 2012), which would be insufficient to
suppress HGP in spite of the persistent increase of IL-6 expres-
sion in obese and insulin-resistant mice.
In this study, we have elucidated the mechanism by which the
vagus nerve suppresses hepatic IL-6/STAT3 signaling activation
via Kupffer cell a7-nAchR-mediated cholinergic activity, as well
as the mechanism by which central insulin action amplifies
hepatic IL-6/STAT3 activity by lowering the activity of the hepatic
branches of the vagus nerve. Moreover, we found the possibility
that central insulin action-mediated control of the vagus nerve is
lost, while cholinergic action has the ability to suppress inflam-
matory cytokine expression in Kupffer cells in obese insulin-
resistant mice. These findings suggest that the aberrant
regulation of Kupffer cells via the vagus nerve and a7-nAchR-
mediated cholinergic action by central insulin action may have2372 Cell Reports 14, 2362–2374, March 15, 2016 ª2016 The Authora significant role in the pathogenesis of chronic hepatic inflam-
mation in obesity.
EXPERIMENTAL PROCEDURES
Mice
Experiments using mice were conducted in accordance with the guidelines for
the care and use of laboratory animals of Kanazawa University. Male mice
(8–10 weeks old) were housed under a 12 hr light-dark cycle with free access
to food and water. Wild-type C57BL/6J Slc mice were purchased from Japan
SLC, and a7KO mice were from Jackson Laboratory. Diet-induced obesity
mice were fed a high-fat diet (60% fat, D12492; Research Diets) for 4 or
6 weeks from 7 weeks of age.
Electro-Physiological Recording of Hepatic VNA
Parasympathetic nerve activity measurements were performed as described
previously (Tanida et al., 2015). In brief, the hepatic branch of the ventral sub-
diaphragmatic vagal nerve was identified and exposed on the esophagus after
incision of the abdominal midline, to measure hepatic VNA. Hepatic VNA was
recorded in separate animals. Each nerve was attached to a pair of 36-gauge
stainless steel wire electrodes and then fixed quickly with a silicone gel (Kwik-
Sil; WPI) to prevent dehydration and provide electrical insulation. After surgery,
each animal was allowed to stabilize for 20–40 min.
Electrical activity in each nerve was amplified 50,000–100,000 times with
a band-pass filter of 100–1,000 kHz and monitored using an oscilloscope.
The amplified and filtered nerve activity was converted to standard pulses
by a window discriminator, which separated discharges from electrical
background noise post-mortem. Both the discharge rates and the neurogram
were sampled with a PowerLab analog-to-digital converter for recording
and data analysis on a computer. Background noise, which was determined
at 30–60 min after the animal was euthanized, was subtracted. Nerve
activity was rectified and integrated with baseline nerve activity normalized
to 100%.
Baseline measurements of hepatic VNA were made at 5–10 min prior to ICV
bolus injection of vehicle (artificial cerebrospinal fluid 2 ml) and human insulin
(40 mU/2 ml). After treatment, nerve activity was monitored for 180 min. At
the end of the experiment, hexamethonium bromide (10 mg/kg body weight)
was administered intravenously to ensure that post-ganglionic efferent para-
sympathetic nerve activity had been recorded.
ICV Administration of Insulin
An internal cannula (Plastics One) was inserted into the lateral ventricle. After
7–10 days of recovery and then a 16 hr fast, the mice received an ICV admin-
istration of human insulin or artificial cerebrospinal fluid (Inoue et al., 2006). An
insulin (10 mU/ml) solution was infused at a fixed rate (1 ml/hr) following bolus
infusion (1 ml/min). The mice received chlorisondamine, neostigmine, nicotine,
bethanechol, atropine, PNU-282987, andMLA (Sigma-Aldrich) with ICV insulin
administration, as described in the figure legends.
Euglycemic Pancreatic-Insulin Clamp Procedure
A euglycemic pancreatic-insulin clamp test was carried out as described pre-
viously with modifications (Kimura et al., 2013). An internal cannula (Plastics
One) was inserted into the lateral ventricle, followed by intravenous cannula-
tion at 7–9 days later. After 4 days of recovery and habituation, we performed
pancreatic clamp with ICV administration. After a 16 hr fast, the mice received
an ICV administration of porcine insulin (Sigma-Aldrich) with an intravenous in-
jection of [3H]glucose (Perkin Elmer), glucose, human insulin (Eli Lilly), and so-
matostatin (SRIF), as shown in Figure 6A. Blood glucose levels were measured
every 10 min and maintained between 90 and 120 mg/dl after starting intrave-
nous injections of insulin and SRIF. Between 90 and 120 min after starting in-
sulin and SRIF administration, the glucose infusion rate and plasma [3H]
glucose-specific activity was measured every 10 min. The rate of disappear-
ance (Rd) under steady-state conditions for plasma glucose concentration
was determined from the rate of [3H]glucose infusion divided by plasma [3H]
glucose-specific activity. The rate of EGP was obtained from the difference
between Rd and glucose infusion rate.s
Kupffer Cell Depletion or Reconstitution by Bone Marrow
Transplantation
Kupffer cell depletion was performed as described previously (Kimura et al.,
2013). For Kupffer cell reconstitution by bone marrow transplantation, we in-
jected liposomal clodronate (Clophosome; FormuMax Scientific) intravenously
at 2 and 3 days before irradiation to deplete Kupffer cells (Seki et al., 2009).
Bone marrow was obtained by flushing the tibias and femurs of donor mice
and then washing twice in ice-cold PBS containing 0.5% BSA. Bone marrow
transplantation was performed by injecting 1.0 3 108 bone marrow cells into
the tail veins of irradiated (4.8 Gy, twice) recipient mice. The ICV insulin injec-
tion study was performed at 6 weeks after bone marrow transplantation. The
efficacy of Kupffer cell reconstitution was evaluated by immunostaining with
an anti-mouse MAC2 antibody (Cedarlane Laboratories) and anti-GFP anti-
body (Medical and Biological Laboratories) in a7KO liver transplanted from
GFP-transgenic mice (Okabe et al., 1997).
Identification, Isolation, and Culture of Kupffer Cells
Kupffer cell counting was performed for the analysis of immunohistochemistry
using an anti-MAC2 antibody (Cedarlane Laboratories). Kupffer cells were iso-
lated as described previously, with minor modifications (Ikeda et al., 2009). In
brief, the liver was perfused through the vena cava with Krebs-Ringer buffer
containing calcium and magnesium ions. Thereafter, the liver was minced
and incubated in a buffer containing 0.1% type 1 collagenase (Worthington
Biochemical) and 150 U/ml DNase for 30 min. The suspension was
filtered through a 100-mm filter membrane and the filtrate was centrifuged
twice at 50 3 g for 4 min at 4C to remove parenchymal cells. The remaining
cell fraction in the supernatant was resuspended in Dulbecco’s modified Eagle
medium (DMEM) containing 10%heat-inactivated fetal calf serum and allowed
to adhere to the bottom of plastic culture dishes for 3 hr. Non-adherent cells
were removed by gentle washing. LPS (Sigma-Aldrich) was added to the cul-
ture medium at a final concentration of 5 ng/ml, and the cells were collected at
3 hr after stimulation with LPS. The cells were pre-treated with the following
agents for 15 min prior to LPS administration: acetylcholine with pyridostig-
mine, bethanechol, nicotine, chlorisondamine, PNU-282987, MLA (Sigma-
Aldrich), DHbE (Tocris Bioscience), and aBgt (Tocris Bioscience).
Analysis of Blood Parameters
Plasma insulin and IL-6 concentration was determined using a mouse insulin
ELISA kit (Shibayagi) and Quantikine Mouse IL-6 ELISA kit (R&D Systems),
respectively. Blood glucose levels were measured using a GLUCOCARD G+
Meter (Arkray). Serum endotoxin concentrations were quantified by a limulus
amoebocyte lysate (LAL kit, QCL-1000; Lonza). Sterile serum samples ob-
tained from portal vein blood were diluted to 20% (vol/vol) with endotoxin-
free water and heated to 70C for 10 min to inactivate serum proteins. Each
assay was performed strictly according to the manufacturers’ protocols.
Western Blotting and qPCR
Immunoblotting was performed using an anti-phosphorylated (phospho)-
STAT3 (Tyr705) antibody (Cell Signaling Technology) and anti-STAT3 antibody
(Santa Cruz Biotechnology). Immunoblot images are representative of at least
three independent immunoblot analyses and quantified by densitometry on an
LAS-3000 Imager (Fujifilm).
The results of qPCR were analyzed using the 36B4 gene as an internal con-
trol and plotted in arbitrary units as mean ± SE. The primer sequences used in
this study are available upon request (36B4, Il6, Emr1, Chrna7 [which encodes
a7-nAchR], and G6pc [which encodes G6Pase]).
Statistical Analysis
Data are represented as mean ± SE. Statistical analysis was performed using
Student’s t test and one-way ANOVA followed by post hoc tests and differ-
ences were considered significant at p values of < 0.05.
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